Alnylam Pharmaceuticals
ALNY
ALNY
450 hedge funds and large institutions have $20.9B invested in Alnylam Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 162 increasing their positions, 163 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
15% less call options, than puts
Call options by funds: $172M | Put options by funds: $203M
26% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 58
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
450
Holding in Top 10
4
Calls
$172M
Puts
$203M
Top Buyers
| 1 | +$86.8M | |
| 2 | +$76M | |
| 3 | +$64.5M | |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$38.5M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$28.6M |
Top Sellers
| 1 | -$214M | |
| 2 | -$119M | |
| 3 | -$40.6M | |
| 4 |
Two Sigma Investments
New York
|
-$39.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$30.7M |